MARKET

SABS

SABS

SAB BIOTHERAPEUTICS INC
NASDAQ
3.960
+0.340
+9.39%
Pre Market: 3.900 -0.06 -1.52% 04:00 05/14 EDT
OPEN
3.620
PREV CLOSE
3.620
HIGH
4.040
LOW
3.572
VOLUME
6
TURNOVER
0
52 WEEK HIGH
6.60
52 WEEK LOW
1.600
MARKET CAP
302.80M
P/E (TTM)
56.98
1D
5D
1M
3M
1Y
5Y
1D
Chardan Capital Keeps Their Buy Rating on SAB Biotherapeutics (SABS)
TipRanks · 1d ago
SAB Biotherapeutics price target raised to $10 from $7 at H.C. Wainwright
TipRanks · 1d ago
SAB Biotherapeutics Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 1d ago
SAB Biotherapeutics Price Target Raised to $10.00/Share From $7.00 by HC Wainwright & Co.
Dow Jones · 1d ago
HC Wainwright & Co. Maintains Buy on SAB Biotherapeutics, Raises Price Target to $10
Benzinga · 1d ago
Full Transcript: SAB Biotherapeutics Q1 2026 Earnings Call
Benzinga · 1d ago
SAB Biotherapeutics reports Q1 results
Seeking Alpha · 1d ago
SAB Biotherapeutics Q1 EPS $(0.35) Misses $(0.20) Estimate.
Benzinga · 1d ago
More
About SABS
SAB Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of human polyclonal immunotherapeutic antibodies, or human immunoglobulin G (hIgG), to address immunology disorders. The Company is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets or best-in-class against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders. The Company’s lead product candidate, SAB-142, is a human anti-thymocyte globulin (ATG) focused on preventing or delaying the progression of T1D. SAB-142 is expected to reduce autoimmune beta cell destruction and delay progression or onset of T1D in patients with Stage III or Stage II T1D. The Company’s genetic engineering platform produces human, multi-targeted, high-potency immunoglobulins, without the need for human donors or convalescent plasma.

Webull offers SAB Biotherapeutics Inc stock information, including NASDAQ: SABS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SABS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SABS stock methods without spending real money on the virtual paper trading platform.